Biotek-snakken — December 2017
-
-
Endnu en god nyhed fra stærke EXEL: Cabozantinib godkendt til frontline RCC 2 mdr før deadline https://seekingalpha.com/news/3319230-fda-oks-exelixis-cabometyx-first-line-kidney-cancer-shares-ahead-3-percent?app=1&uprof=45&dr=1#email_link
-
Lidt om outlook for Exelixis i denne artikel https://finance.yahoo.com/news/exelixis-apos-cabometyx-takes-aim-190000425.html
-
Min nye analyse på Nuevolution: http://www.proinvestor.com/aktieanalyser/255/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind